Long-Acting Beta Agonists Enhance Allergic Airway Disease

Knight, John; Mak, Garbo; Shaw, Joanne; Porter, Paul B.; McDermott, Catherine; Roberts, Luz; You, Ran; Yuan, Xiaoyi; Millien, Valentine O.; Qian, Yuping; Li, Song; Vincent, Frazier; Kim, Choel; Kim, Jeong Joo; Bond, Richard A.; Milner, Joshua D.; Zhang, Yuan; Mandal, Pijus K.; Luong, Amber U.; Kheradmand, Farrah; McMurray, John S.; Corry, David B.

doi:10.1371/journal.pone.0142212

Cited by 14 publications

(11 citation statements)

References 65 publications

(74 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite effectively bronchodilating the airways even when administered for extended periods of time (especially partial agonists such as salmeterol), β 2 -agonists increase airway responsiveness 50 , 51 . Moreover, these drugs induce vasodilation as well as bronchodilation, which could facilitate the influx of inflammatory cells into the airways or participate in airway wall thickening while masking clinical symptoms 52 . Based on our data, we cannot conclude about the effect of the treatments studied on the number of inflammatory cells into the airways, as the volume of the bronchoalveolar lavage recovered is variable and related to the degree of collapse of the airways in horses.…”

Section: Discussionmentioning

confidence: 99%

Fluticasone/salmeterol reduces remodelling and neutrophilic inflammation in severe equine asthma

Bullone

Vargas

Elce

et al. 2017

Sci Rep

View full text Add to dashboard Cite

Asthmatic airways are inflamed and undergo remodelling. Inhaled corticosteroids and long-acting β2-agonist combinations are more effective than inhaled corticosteroid monotherapy in controlling disease exacerbations, but their effect on airway remodelling and inflammation remains ill-defined. This study evaluates the contribution of inhaled fluticasone and salmeterol, alone or combined, to the reversal of bronchial remodelling and inflammation. Severely asthmatic horses (6 horses/group) were treated with fluticasone, salmeterol, fluticasone/salmeterol, or with antigen avoidance for 12 weeks. Lung function, central and peripheral airway remodelling, and bronchoalveolar inflammation were assessed. Fluticasone/salmeterol and fluticasone monotherapy decreased peripheral airway smooth muscle remodelling after 12 weeks (p = 0.007 and p = 0.02, respectively). On average, a 30% decrease was observed with both treatments. In central airways, fluticasone/salmeterol reversed extracellular matrix remodelling after 12 weeks, both within the lamina propria (decreased thickness, p = 0.005) and within the smooth muscle layer (p = 0.004). Only fluticasone/salmeterol decreased bronchoalveolar neutrophilia (p = 0.03) to the same extent as antigen avoidance already after 8 weeks. In conclusion, this study shows that fluticasone/salmeterol combination decreases extracellular matrix remodelling in central airways and intraluminal neutrophilia. Fluticasone/salmeterol and fluticasone monotherapy equally reverse peripheral airway smooth muscle remodelling.

show abstract

Section: Discussionmentioning

confidence: 99%

Fluticasone/salmeterol reduces remodelling and neutrophilic inflammation in severe equine asthma

Bullone

Vargas

Elce

et al. 2017

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Persistent pulmonary inflammation and tissue remodeling result in the gradual decline in pulmonary function in patients suffering from chronic lung diseases including chronic obstructive pulmonary disease (COPD), asthma, and idiopathic pulmonary fibrosis (IPF) ( 3 , 12 – 16 ). Chronic lung disease ranks the third leading cause of death in the United States.…”

Section: Introductionmentioning

confidence: 99%

Adenosine at the Interphase of Hypoxia and Inflammation in Lung Injury

Berg

Mills

et al. 2021

Front. Immunol.

Self Cite

View full text Add to dashboard Cite

Hypoxia and inflammation often coincide in pathogenic conditions such as acute respiratory distress syndrome (ARDS) and chronic lung diseases, which are significant contributors to morbidity and mortality for the general population. For example, the recent global outbreak of Coronavirus disease 2019 (COVID-19) has placed viral infection-induced ARDS under the spotlight. Moreover, chronic lung disease ranks the third leading cause of death in the United States. Hypoxia signaling plays a diverse role in both acute and chronic lung inflammation, which could partially be explained by the divergent function of downstream target pathways such as adenosine signaling. Particularly, hypoxia signaling activates adenosine signaling to inhibit the inflammatory response in ARDS, while in chronic lung diseases, it promotes inflammation and tissue injury. In this review, we discuss the role of adenosine at the interphase of hypoxia and inflammation in ARDS and chronic lung diseases, as well as the current strategy for therapeutic targeting of the adenosine signaling pathway.

show abstract

“…118 STAT6 has been found to be up-regulated in airways of asthmatic patients, 119,120 and transgenically engineered STAT6 -/-mice have complete absence of IL-4/IL-13 allergic airway responses. 121,122 As a result, cell membrane-permeable SMDs that inhibit the activation of the JAK STAT pathway have been developed. An orally administered JAK1 and JAK2 inhibitor, baricitinib, has proven efficacious in phase 2 DBRCTs in AD.…”

Section: Small-molecule Drugs (Smds)mentioning

confidence: 99%

Targetable pathogenic mechanisms in nasal polyposis

Schneider¹,

Schleimer

Tan

2021

Int Forum Allergy Rhinol

View full text Add to dashboard Cite

Chronic rhinosinusitis with nasal polyps (CRSwNP) represents a challenging disease entity with significant rates of recurrence following appropriate medical and surgical therapy. Recent approval of targeted biologics in CRSwNP compels deeper understanding of underlying disease pathophysiology. Both of the approved biologics for CRSwNP modulate the type 2 inflammatory pathway, and the majority of drugs in the clinical trials pathway are similarly targeted. However, there remain multiple other pathogenic mechanisms relevant to CRSwNP for which targeted therapeutics already exist in other inflammatory diseases that have not been studied directly. In this article we summarize pathogenic mechanisms of interest in CRSwNP and discuss the results of ongoing clinical studies of targeted therapeutics in CRSwNP and other related human inflammatory diseases.

show abstract

Long-Acting Beta Agonists Enhance Allergic Airway Disease

Cited by 14 publications

References 65 publications

Fluticasone/salmeterol reduces remodelling and neutrophilic inflammation in severe equine asthma

Fluticasone/salmeterol reduces remodelling and neutrophilic inflammation in severe equine asthma

Adenosine at the Interphase of Hypoxia and Inflammation in Lung Injury

Targetable pathogenic mechanisms in nasal polyposis

Contact Info

Product

Resources

About